Brief: Theranexus FY Operating Loss Widens To 7.4 Million Euros

Thx Pharma SA

09/04/2020 18:08

April 9 (Reuters) - THERANEXUS SA  ALTHX.PA :
    * 2019 FULL-YEAR RESULTS AND UPDATE ON ACTIVITIES
    * CONTROLLED CASH CONSUMPTION OVER FISCAL YEAR 2019
    * THE COMPANY'S CASH AMOUNTED TO €7,807 K AT MARCH 31 2020
    * THE OPERATING LOSS INCREASED SLIGHTLY FROM -€6,990 K IN
2018 TO
-€7,377 K IN 2019
    * COMPANY IS IN A POSITION TO MEET ITS FINANCIAL OBLIGATIONS
IN
THE COMING 12 MONTH
    * PROMISING PROSPECTS FOLLOWING THE RECENT SUCCESS OF THE
PHASE II
TRIAL FOR THN102 IN PARKINSON’S PATIENTS
    * CURRENTLY PURSUING PRECLINICAL SELECTION AND
CHARACTERIZATION
ACTIVITIES FOR UPCOMING DRUG CANDIDATES EXPECTED TO FURTHER
EXPAND THE COMPANY'S CLINICAL PROJECT PORTFOLIO
    * PORTFOLIO BROADENED WITH A NEW DRUG CANDIDATE BBDF-101
FURTHER
TO THE EXECUTION OF AN AGREEMENT WITH THE BEYOND BATTEN DISEASE
FOUNDATION

Source text for Eikon:  ID:nACT62926 
Further company coverage:  ALTHX.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))